Search

Displaying results 1561 - 1570 of 6076 in total
  1. Drug

    Lumasiran

    go.drugbank.com/drugs/DB15935
    ApprovedInvestigational

    [L23554] Oxlumo, producted by Alnylam Pharmaceuticals, represents the first approved treatment for PH1.

  2. Drug

    Ozenoxacin

    go.drugbank.com/drugs/DB12924
    Approved

    s Xepi (ozenoxacin 1%) as a topically applied cream indicated for the treatment of impetigo caused by *Staphylococccus aureus* or *Streptococcus pyogenes* in adult and pediatric patients 2 months of age

    Categories: Antibiotics for Topical Use
  3. Drug

    Tebentafusp

    go.drugbank.com/drugs/DB15283
    ApprovedInvestigational

    [L39995] Tebentafusp was subsequently approved for the same indication in the EU in April 2022.[L41675] … [A244815] On January 26, 2022, tebentafusp was first approved by the FDA for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma.

  4. Drug

    Setmelanotide

    go.drugbank.com/drugs/DB11700
    ApprovedInvestigational

    Setmelanotide is the first available treatment for patients with pro-opiomelanocortin, proprotein subilisin/kexin type 1, or leptin deficiencies. … [A224449] Other earlier treatments for these patients included gastric bypass surgery.[A224449] Patients taking setmelanotide experienced an average weight loss of 0.6 kg/week.

  5. Drug

    Finerenone

    go.drugbank.com/drugs/DB16165
    ApprovedInvestigational

    [A236544] So far, finerenone is the only nonsteroidal mineralocorticoid receptor antagonist to be FDA approved. … [A236544] Spironolactone has low selectivity and affinity for the receptor; it dissociates quickly and can also have effects at the androgen, progesterone, and glucocorticoid receptors.

  6. Drug

    Fluticasone

    go.drugbank.com/drugs/DB13867
    ApprovedInvestigationalWithdrawn

    These drugs are available as inhalers, nasal, sprays, and topical treatments for various inflammatory indications[F4355,F4358,F4361,F4364][FDA Label].

    Categories: Corticosteroids for inhalation use, Drugs for Obstructive Airway Diseases
  7. Drug

    Deutetrabenazine

    go.drugbank.com/drugs/DB12161
    ApprovedInvestigational

    Deutetrabenazine is a novel, highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the management of chorea associated with Huntington’s disease. … As with other agents for the treatment of neurodegenerative diseases, deutetrabenazine is a drug to alleviate the motor symptoms of HD and is not proposed to halt the progression of the disease [T28].

  8. Drug

    Belantamab mafodotin

    go.drugbank.com/drugs/DB15719
    ApprovedInvestigationalWithdrawn

    [A216756] Belantamab mafodotin was granted FDA accelerated approval on 5 August 2020 for the treatment of multiple myeloma;[L15326] however, its manufacturer began the process for withdrawal of the … [L44236] In July of 2025, belantamab mafodotin was approved by Health Canada for a similar indication, but for use in combination with either [Dexamethasone] and [Bortezomib] or [Dexamethasone] and [Pomalidomide

  9. Drug

    Deuruxolitinib

    go.drugbank.com/drugs/DB18847
    ApprovedInvestigational

    [A264113] On July 26, 2024, deuruxolitinib was approved by the FDA for the treatment of severe alopecia areata.

  10. Drug

    Potassium perchlorate

    go.drugbank.com/drugs/DB09418
    ApprovedWithdrawn

    Thus the use of potassium perchlorate has been extensive for hyperthyroidism during the last 50 years, particularly in the late 1950s and early 1960s [A32609]. … The therapeutic use of potassium perchlorate in thyroid disorders has been ceased due to a high risk for developing aplastic anemia and nephrotic syndrome [L2364].